What are your top takeaways from SGO 2023?
There were many great presentations at SGO 2023 along with a few practice changing presentations. Two pivotal randomized phase III clinical trials enrolled advanced, metastatic endometrial cancer patients. Each demonstrated dramatic benefit with the addition of immunotherapy to chemotherapy (followe...
- GOG-3026 Phase II trial Letrozole = Ribociclib of low grade ovarian cancer. This gives us another treatment for this disease to be added to hormonal therapy and MEK inhibitor trametinib.
- All of the abstracts on Circulating cell free DNA analysis. These usher in a new era of real-time genetic evalua...
I found the NOW trial to be the most provocative of the studies presented that I was able to attend.
In this study, the authors were trying to determine the feasibility of olaparib in the neoadjuvant setting for ovarian cancer. Patients had a germline BRCA1/2, RAD51C/D, or PALB2 mutation and high g...
- Late breaking IO in endometrial cancer
- Ribo + letrozole - GOG-3026… not earth-shattering but we all need more therapy options for LGSC, happy to see this data supporting another option/line.
- New staging for endometrial cancer presentation - not live yet, but a lot of information to digest so good ...
- NRG-GY018 (Dr. @Dr. First Last) and RUBY (Dr. Mirza) are prospective clinical trials that change the way we approach the treatment of metastatic and recurrent endometrial cancer. Immunotherapy use will expand greatly as we see significant benefits for patients with MMR proficient and MMR deficient ...
All three will end up as options for care. The FDA will see the applications for pembro and dostar soon and will make a decision on just dMMR or all comers. That’s practice impactful. The LGSOC has a good chance of compendia listing and could be used in practice but it als...
- Pembrolizumab and Dostarlimab presentations at late breaking on Monday. How will the treatment of 1L chemo for metastatic or recurrent endometrial change? What will the FDA allow us to use? How does the FDA judge this data?
- The choice of clinical trials for our patient’s treatment may lead to super...